Customize your JAMA Network experience by selecting one or more topics from the list below.
Gallo S, Comeau K, Vanstone C, et al. Effect of Different Dosages of Oral Vitamin D Supplementation on Vitamin D Status in Healthy, Breastfed Infants: A Randomized Trial. JAMA. 2013;309(17):1785–1792. doi:10.1001/jama.2013.3404
Author Affiliations: School of Dietetics and Human Nutrition, McGill University (Mss Gallo, Comeau, Vanstone, and Agellon and Drs Rodd and Weiler), Montreal Children's Hospital, McGill University Health Centre (Drs Sharma and Rodd), and Europharm International Canada Inc (Dr Khamessan), Montréal, Québec, Canada; Departments of Biomedical and Molecular Sciences and Medicine, Queen's University, Kingston, Ontario, Canada (Dr Jones); and Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada (Dr L’Abbé).
Importance Vitamin D supplementation in infancy is required to support healthy bone mineral accretion. A supplement of 400 IU of vitamin D per day is thought to support plasma 25-hydroxyvitamin D (25[OH]D) concentrations between 40 and 50 nmol/L; some advocate 75 to 150 nmol/L for bone health.
Objective To investigate the efficacy of different dosages of vitamin D in supporting 25(OH)D concentrations in infants.
Design, Setting, and Participants Double-blind randomized clinical trial conducted among 132 one-month-old healthy, term, breastfed infants from Montréal, Québec, Canada, between March 2007 and August 2010. Infants were followed up for 11 months ending August 2011 (74% completed study).
Intervention Participants were randomly assigned to receive oral cholecalciferol (vitamin D3) supplements of 400 IU/d (n=39), 800 IU/d (n=39), 1200 IU/d (n=38), or 1600 IU/d (n=16).
Main Outcomes and Measures The primary outcome was a plasma 25(OH)D concentration of 75 nmol/L or greater in 97.5% of infants at 3 months. Secondary outcomes included 25(OH)D concentrations of 75 nmol/L or greater in 97.5% of infants at 6, 9, and 12 months; 25(OH)D concentrations of 50 nmol/L or greater across all times; growth; and whole body and regional bone mineral content. Data were analyzed by intention to treat using available data, logistic regression, and mixed-model analysis of variance.
Results By 3 months, 55% (95% CI, 38%-72%) of infants in the 400-IU/d group achieved a 25(OH)D concentration of 75 nmol/L or greater vs 81%(95% CI, 65%-91%) in the 800-IU/d group, 92% (95% CI, 77%-98%) in the 1200-IU/d group, and 100% in the 1600-IU/d group. This concentration was not sustained in 97.5% of infants at 12 months in any of the groups. The 1600-IU/d dosage was discontinued prematurely because of elevated plasma 25(OH)D concentrations. All dosages established 25(OH)D concentrations of 50 nmol/L or greater in 97% (95% CI, 94%-100%) of infants at 3 months and sustained this in 98% (95% CI, 94%-100%) to 12 months. Growth and bone mineral content did not differ by dosage.
Conclusions and Relevance Among healthy, term, breastfed infants, only a vitamin D supplement dosage of 1600 IU/d (but not dosages of 400, 800, or 1200 IU/d) increased plasma 25(OH)D concentration to 75 nmol/L or greater in 97.5% of infants at 3 months. However, this dosage increased 25(OH)D concentrations to levels that have been associated with hypercalcemia.
Trial Registration clinicaltrials.gov Identifier: NCT00381914
Create a personal account or sign in to: